# Clinical Trials Data KIT - Document 17

# Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia

## Clinical Trial: https://clinicaltrials.gov/study/NCT01066286

"eligibilityCriteria": "Inclusion Criteria:\n\n\* patients with core binding factor positive acute myeloid leukemia\n\* 18 years or older\n\* patients were treated with standard chemotherapy\n\* patients with available medical record and stored bone marrow specimen at time of diagnosis\n\nExclusion Criteria:\n\n\* no definive criteria",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "core binding factor positive acute myeloid leukemia",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the clinical trial information provided, a patient with a KIT gene mutation would be eligible to participate in the trial if they meet the following criteria:  
  
1. \*\*Core Binding Factor Positive AML:\*\* The patient must have core binding factor positive acute myeloid leukemia (AML). This is the primary inclusion criterion for the trial. The presence of a KIT mutation is common in patients with core binding factor AML, but the mutation itself is not listed as an exclusion criterion. Therefore, the presence of a KIT mutation does not automatically disqualify the patient, provided they are core binding factor positive.  
  
2. \*\*Age:\*\* The patient must be 18 years or older.  
  
3. \*\*Previous Treatment:\*\* The patient must have been treated with standard chemotherapy.  
  
4. \*\*Medical Records and Specimen Availability:\*\* The patient must have available medical records and a stored bone marrow specimen from the time of diagnosis.  
  
Given that the exclusion criteria do not include KIT mutations, and assuming the patient meets the above criteria, a patient with a KIT gene mutation would be eligible for this clinical trial.